Physician profile
Arkady Massen
NPI 1306943626
$731.18
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $62.49 · 2021: $462 · 2023: $14.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $127.18 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.66 | 2021 | |
| Astellas Pharma US INC | $99.00 | 2021 | |
| Sun Pharmaceutical Industries INC. | $68.95 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $35.74 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.95 | 2019-2023 | Xifaxan |
| Ethicon US, LLC | $30.66 | 2021 | |
| Abbott Laboratories | $25.61 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.34 | 2020 | |
| Vanda Pharmaceuticals INC. | $20.40 | 2021 | |
| Irhythm Technologies, INC. | $19.69 | 2019 | |
| Glaxosmithkline, LLC. | $19.01 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.63 | 2021 | |
| Merck Sharp & Dohme LLC | $17.93 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $17.67 | 2021 | |
| Eisai INC. | $17.61 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arkady Massen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.